Updated:
US Army Medical Research and Material Command
The US Army Medical Research and Material Command, part of the US Army Medical Department, coordinates medical R&D across more than a dozen specialized...
US Army Medical Research and Material Command
The US Army Medical Research and Material Command, part of the US Army Medical Department, coordinates medical R&D across more than a dozen specialized research units including the Walter Reed Army Institute of Research and the US Army Institute of Surgical Research. It was formally established in 1993 as the successor to earlier medical research directorates. Its mission spans basic science through advanced development of medical materiel—vaccines, drugs, diagnostics, devices, and training systems—for military use. USAMRMC's research portfolio covers infectious diseases (malaria, dengue, COVID-19), combat casualty care, blast injury, psychological health, and chemical/biological defense. It manages the Congressionally Directed Medical Research Programs, which fund extramural peer-reviewed research in breast cancer, prostate cancer, and other areas through specific appropriations. Notable products include the FDA-licensed RTS,S malaria vaccine and the freeze-dried plasma used in battlefield transfusions. Geographic footprint is predominantly US-based across installations in Maryland, Texas, Alabama, and Washington state, with international collaborations through overseas labs in Kenya, Thailand, and Germany. The command employs over 5,000 military and civilian personnel across its enterprise; its annual budget exceeds $1 billion, largely from congressional appropriations. It operates as a government research entity, not a private fund or single-family office. Recent operational events include restructuring of its medical materiel development functions: in 2020, the US Army established the Medical Research and Development Command (USAMRDC) as a higher-echelon organization, with USAMRMC becoming a subordinate component focused on research and acquisition under the Army Futures Command's oversight. USAMRMC's structural differentiator is its integration into the military acquisition system: it develops medical products for a single customer—the US warfighter—using federal R&D funding and regulatory pathways specific to military medical countermeasures. Unlike civilian biotech or pharma, it does not seek commercial profit; its mandate is readiness-driven medical capability. Succession follows military command rotation, with a brigadier general typically serving as commander for two to three years.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
—
Corporate office
United States
Sector focus
Frequently asked questions
What is the role of the US Army Medical Research and Material Command?
USAMRMC directs and coordinates biomedical research, development, and acquisition for military medical needs. Its subordinate units develop vaccines, drugs, diagnostics, devices, and training systems for force health protection. The command also manages the Congressionally Directed Medical Research Programs, which fund extramural research in disease areas such as breast cancer and prostate cancer (per public record).
Is USAMRMC a funding agency or does it perform its own research?
Both. It operates intramural laboratories—including the Walter Reed Army Institute of Research and the US Army Institute of Surgical Research—that conduct in-house research. It also administers extramural research programs through competitive grants and contracts. The command's acquisition arm manages product development and procurement contracts (per public record).
How does USAMRMC's budget compare to NIH or private biotech?
USAMRMC's annual budget is in the range of $1–2 billion, a small fraction of the National Institutes of Health's roughly $45 billion per year. Its research portfolio is narrower, focused on military-specific needs rather than broad medical research, but it has developed important products used in both military and civilian settings (per public record).
What are some notable medical products developed by USAMRMC?
Products include the RTS,S/AS01 malaria vaccine, licenced by the FDA in 2015, and freeze-dried plasma (FDP) for battlefield transfusion, approved by the FDA in 2018. USAMRMC also developed the Jeryl Lynn strain mumps vaccine and contributed to the development of the anthrax vaccine (per public record and the Walter Reed Army Institute of Research website).
How is USAMRMC organized?
USAMRMC is part of the US Army Medical Department and under the command of a brigadier general. It includes multiple subordinate commands: the Walter Reed Army Institute of Research (infectious disease), the US Army Institute of Surgical Research (burn and trauma), and the US Army Medical Materiel Development Activity (acquisition). The command was restructured in 2020 under the new US Army Medical Research and Development Command (per Department of Defense organizational documents).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: